Rodent Research-3, a study sponsored by Eli Lilly and Company and the Center for the Advancement of Science in Space (CASIS), focuses on assessing the ability of a novel compound to prevent skeletal muscle wasting and weakness in mice exposed to long-duration spaceflight. The investigation launched aboard the eighth SpaceX resupply mission to the space station on April 8.
How can spaceflight help researchers better understand terrestrial musculoskeletal diseases and interventions? When we unload, or remove the force of our body weight from the muscles that normally work against gravity to support us, those muscles rapidly atrophy, or waste away and weaken. That’s exactly what happens in microgravity unless countermeasures are applied. The astronauts on the space station, for example, follow rigorous exercise programs that apply forces to their musculoskeletal systems and help them stay strong throughout their missions.
Mice exposed to spaceflight have proved to be valuable research models to understand, target and treat causes of human muscle atrophy.
“This includes modeling serious diseases that involve muscle wasting such as muscular dystrophy, amyotrophic lateral sclerosis, cancer cachexia and even aging-related musculoskeletal frailty,” said Rosamund Smith, research fellow at Eli Lilly and Company, and the principal investigator for the Rodent Research-3 mission.
“The ability to expose all muscles of an organism to conditions that induce muscle atrophy is not easily achieved on Earth,” said Smith. “Lilly is excited to have the opportunity to conduct this investigation in space.”
Loss of muscle function, rather than just a decrease in muscle size, is the critical aspect that leads to problems with physical performance in patients suffering from muscle-wasting conditions. Therefore, Eli Lilly and Company has contributed expertise, techniques and equipment for studying muscle function in the mission.
“The Rodent Research-3 study is unique not only in the experimental compound that will be tested, but also because, for the first time, muscle function of the mice will be assessed during spaceflight,” said Janet Beegle, Rodent Research-3 project manager at NASA’s Ames Research Center in California’s Silicon Valley.
Rodent Research-3 uses NASA’s Rodent Research Hardware System.Developed and built at Ames, this system takes advantage of experience gained from 27 prior flight investigations with rodents using a space shuttle-based system. The space station now supports much longer-duration rodent studies than were previously possible during space shuttle missions, which were typically two weeks in duration. Rodent Research-3 is a six-week long study.
Although the primary research focus of Rodent Research-3 is skeletal muscle, the investigators are studying other organ systems, such as bone, both at the tissue and molecular levels. Their goal is to characterize tissue responses to spaceflight and observe how these changes vary with the length of time spent in microgravity. The findings will advance our understanding of the risks that long-term space exploration poses to astronauts, and can be applied towards the development of countermeasures to protect astronaut health. Additionally, Eli Lilly and Company plans to share Rodent Research-3 experimental samples with the scientific community, further broadening the potential benefits of this research mission.
Results from Rodent Research-3 will be applied to ongoing discovery efforts at Eli Lilly and Company, seeking treatments for serious muscle-wasting diseases and conditions that may potentially help patients afflicted with degenerative diseases to stay strong.
The space station is a blueprint for global cooperation and scientific advancements, a destination for growing a commercial marketplace in low-Earth orbit, and a test bed for demonstrating new technologies. The orbiting laboratory is also the major springboard to NASA’s next great leap in exploration, including future missions to an asteroid and Mars.